ARCHIVES

NCAB Decides To End IGs, Review total Research Support, And Consider P01 Limitation

This article is from The Cancer Letter archive.

Vol. 18 No. 24 | June 12, 1992

Download PDF Visit The Full Archive

Related Articles

Amgen Cancels Rilotumumab Trials in Gastric Cancer

December 26, 2014

Increase Cancer Center Grants More Than R01s, SPOREs, Report Tells NCI

February 28, 2003

Study Of Tamoxifen And Raloxifene Enrolls 6,000 In First Year; 5 Percent Are Minorities

July 28, 2000

Fluoride Study Update Finds No Increased Risk

October 19, 1990

NCCTG Plans To Conduct Phase II Study Of Brostallicin Plus Cisplatin For mTNBC

April 30, 2010

DCBDC Advisors Okay New Program In Breast Cancer

July 3, 1992